Meeting
2023 ASCO Annual Meeting
Use of PLR and NLR to evaluate the efficacy and prognosis of neoadjuvant chemotherapy with lobaplatin in triple-negative breast cancer.
Authors
Cheng Wang
Southwest Hospital, Army Medical University, Chongqing, China
Cheng Wang , Qiyun Shi , Guozhi Zhang , Wenting Yan , Xiujuan Wu , Andi Wan , Siyi Xiong , Long Yuan , Hao Tian , Dandan Ma , Jun Jiang , Yi Zhang , Xiaowei Qi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
ChiCTR-TRC-14005019
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 594)
DOI
10.1200/JCO.2023.41.16_suppl.594
Abstract #
594
Poster Bd #
424
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.
First Author: Cheng Wang
Poster
2022 ASCO Annual Meeting
Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.
First Author: Jing Luo
Poster
2021 ASCO Annual Meeting
Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.
First Author: Fangchao Zheng
Poster
2019 ASCO Annual Meeting
CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).
First Author: William M. Sikov